• 1
    World Health Organization. World Health Report 2004: Changing History. Statistical annex Table 2: Deaths by cause, sex, and mortality stratum in WHO regions, estimates for 2002. Geneva, Switzerland: World Health Organization; 2004.
  • 2
    Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):21952207.
  • 3
    Downs JR, Clearfield M, Tyroler HA, et al. Air force/Texas coronary atherosclerosis prevention study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol. 2001;87(9):10741079.
  • 4
    Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics—2006 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation. 2006;113(6):e85e151.
  • 5
    D’agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation. 2008;117(6):743753.
  • 6
    Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):9871003.
  • 7
    Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336(7659):14751482.
  • 8
    Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds risk score for men. Circulation. 2008;118(22):22432251.
  • 9
    Lauer MS. Primary prevention of atherosclerotic cardiovascular disease: the high public burden of low individual risk. JAMA. 2007;297(12):13761378.
  • 10
    Kappagoda CT, Amsterdam EA. Assessment of risk for developing coronary heart disease in asymptomatic individuals. J Cardiopulm Rehabil Prev. 2009;29:207219.
  • 11
    Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet. 2004;364:937952.
  • 12
    Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358(13):13361345.
  • 13
    Lester SJ, Eleid MF, Khandheria BK, Hurst RT. Carotid intima-media thickness and coronary artery calcium score as indications of subclinical atherosclerosis. Mayo Clin Proc. 2009;84(3):229233.
  • 14
    Tsang TS, Barnes ME, Gersh BJ, et al. Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography. J Am Coll Cardiol. 2003;42(7):11991205.
  • 15
    Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008; 21(2), 93111.
  • 16
    Greenland P, Bonow RO, Brundage BH, et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA writing committee to update the 2000 expert consensus document on electron beam computed tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol. 2007;49(3):378402.
  • 17
    Schomig A, Mehilli J, De Waha A, et al. A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease. J Am Coll Cardiol. 2008;52(11):894904.
  • 18
    Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) study, 1987-1993. Am J Epidemiol. 1997;146(6):483494.
  • 19
    O’leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340(1):1422.
  • 20
    Chambless LE, Folsom AR, Clegg LX, et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2000;151(5):478487.
  • 21
    Lorenz MW, Von Kegler S, Steinmetz H, et al. Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the Carotid Atherosclerosis Progression Study (CAPS). Stroke. 2006;37(1):8792.
  • 22
    Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation. 1993;87(3 suppl):II56II65.
  • 23
    Kitamura A, Iso H, Imano H, et al. Carotid intima-media thickness and plaque characteristics as a risk factor for stroke in Japanese elderly men. Stroke. 2004;35(12):27882794.
  • 24
    Rosvall M, Janzon L, Berglund G, et al. Incident coronary events and case fatality in relation to common carotid intima-media thickness. J Intern Med. 2005;257(5):430437.
  • 25
    Van Der Meer IM, Bots MI, Hofman A, et al. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation. 2004;109(9):10891094.
  • 26
    Salonen JT, Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb. 1991;11(5):12451249.
  • 27
    Belcaro G, Nicolaides An, Ramaswami G, et al. Carotid and femoral ultrasound morphology screening and cardiovascular events in low risk subjects: a 10-year follow-up study. Atherosclerosis. 2001;156(2):379387.
  • 28
    Howard G, Sharrett AR, Heiss G, et al. Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC investigators. Stroke. 1993;24(9):12971304.
  • 29
    Tzou WS, Douglas PS, Srinivasan SR, et al. Distribution and predictors of carotid intima-media thickness in young adults. Prev Cardiol. 2007;10(4):181189.
  • 30
    Folsom AR, Kronmal RA, Detrano RC, et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med. 2008;168(12):13331339.
  • 31
    Prati P, Tosetto A, Vanuzzo D, et al. Carotid intima media thickness and plaques can predict the occurrence of ischemic cerebrovascular events. Stroke. 2008;39(9):24702476.
  • 32
    Shlipak MG, Katz R, Kestenbaum B, et al. Clinical and subclinical cardiovascular disease and kidney function decline in the elderly. Atherosclerosis. 2009;204(1):298303.
  • 33
    Mendoza FB, Rafii DS, Gransar F, et al. Does zero coronary or aortic calcium score predict absence of carotid plaque? J Am Coll Cardiol. 2008;51(10):A152 [abstract 907–255].
  • 34
    Kramer H, Han C, Post W, et al. Racial/ethnic differences in hypertension and hypertension treatment and control in the multi-ethnic study of atherosclerosis (MESA). Am J Hypertens. 2004;17(10):963970.
  • 35
    Crouse JR 3rd, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA. 2007;297(12):13441353.
  • 36
    Bots ML, Palmer MK, Dogan S, et al; METEOR Study Group. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. J Intern Med. 2009;265(6):698707.
  • 37
    Yu CM, Zhang Q, Lam L, et al. Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease. Heart. 2007;93(8):933939.
  • 38
    Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis In Native Diabetics Study) trial. J Am Coll Cardiol. 2008;52(25):21982205.
  • 39
    Kastelein JJ, Akdim F, Stroes ES, et al; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:14311443.
  • 40
    Meaney A, Ceballos G, Asbun J, et al. The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol. 2009;49(7):838847.
  • 41
    Zhu S, Su G, Meng Qh. Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. Clin Chem. 2006;52(11):20362042.
  • 42
    Hiukka A, Westerbacka J, Leinonen ES, et al. Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. J Am Coll Cardiol. 2008;52(25):21902197.
  • 43
    Taylor AJ, Villines TC, Stanek EJ. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361(22):21132122.
  • 44
    Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007;370(9582):153160.
  • 45
    Vergeer M, Bots ML, Van Leuven SI, et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation. 2008;118(24):25152522.
  • 46
    Meuwese MC, De Groot E, Duivenvoorden R, et al. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA. 2009;301(11):11311139.
  • 47
    Napoli C, Bruzzese G, Ignarro LJ, et al. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Am Heart J. 2008;156(6):1154.
  • 48
    Lonn EM, Gerstein HC, Sheridan P, et al. Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). J Am Coll Cardiol. 2009;53(22):20282035.
  • 49
    Baguet JP, Asmar R, Valensi P, et al. Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. Vasc Health Risk Manag. 2009;5(1):175183.
  • 50
    Ikeda H, Minamikawa J, Nakamura Y, et al. Comparison of effects of amlodipine and angiotensin receptor blockers on the intima-media thickness of carotid arterial wall (AAA study: amlodipine vs. ARB in atherosclerosis study). Diabetes Res Clin Pract. 2009;83(1):5053.
  • 51
    Zanchetti A, Bond MG, Hennig M, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002;106:24222427.
  • 52
    Zanchetti A, Hennig M, Hollweck R, et al. Baseline values but not treatment-induced changes in carotid intima-media thickness predict incident cardiovascular events in treated hypertensive patients: findings in the European Lacidipine Study on Atherosclerosis (ELSA). Circulation. 2009;120(12):10841090.
  • 53
    Hodis HN, Mack WJ, Dustin L, et al. High-dose B vitamin supplementation and progression of subclinical atherosclerosis: a randomized controlled trial. Stroke. 2009;40(3):730736.